Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ Technology, to develop and commercialize a ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Astrazeneca is set to report earnings next week after a turbulant few months for the FTSE 100 firm and its China arm.

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

Some of the major updates include the approval of acalabrutinib (Calquence) for first-line treatment of mantle cell lymphoma, the FDA’s priority review of fam-trastuzumab deruxtecan-nxki (T-DXd; ...

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's National Medical Products Administration (NMPA) as a single agent for adult patients with a specific type of non ...

The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...